Alector lays off 17% of staff after phase 2 Alzheimer's drug fail
5 days ago · Alector removed AL003 from its pipeline but continued work with AbbVie on AL002. Across both AL002 and AL003, the deal was worth up to $985.6 million in option exercise and milestone payments ...
Alector turns to layoffs as Alzheimer’s drug fails
6 days ago · Alector recorded a net loss of $42 million during the third quarter. AL002 is an antibody drug designed to activate a protein found on the surface of certain cells made in the bone marrow. Studies suggests this “TREM2” protein performs a variety of important functions , with one being the promotion of immune cells that reside in the brain.
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II ...
5 days ago · Alector is kicking off a resource realignment effort that will include a workforce reduction. The biotech expects its current cash position to last it through 2026. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals ...
Alector Therapeutics’ novel Alzheimer’s strategy fails in ... - STAT
6 days ago · Alector Therapeutics said Monday that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what had been one of the leading dark horse approaches to treating the ...
Alector stock drops after Alzheimer’s drug fails in Phase II trial
5 days ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. Tech. ... AL002 is a monoclonal antibody that Alector was developing to slow down Alzheimer’s ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid …
5 days ago · As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide a runway through 2026.
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in ...
6 days ago · SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Press Releases - Alector
Aug 29, 2024 · Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial
6 days ago · Alector Contacts: Alector Katie Hogan 202-549-0557 [email protected]. 1AB (media) Dan Budwick 973-271-6085 [email protected]. Argot Partners (investors) Laura Perry 212-600-1902
Alector Plummets After Alzheimer's Drug Trial Fails Primary …
6 days ago · The stock was down 33.6% to $2.63 in late trading, well under its 52-week low of $3.49. The South San Francisco, Calif.-based biotech company said that, after the results of the study, it is ...